AstraZeneca PLC (NASDAQ:AZN – Get Free Report) was the recipient of a large growth in short interest in the month of December. As of December 31st, there was short interest totalling 12,690,000 shares, a growth of 26.1% from the December 15th total of 10,060,000 shares. Based on an average daily trading volume, of 5,590,000 shares, the days-to-cover ratio is presently 2.3 days.
Analyst Ratings Changes
AZN has been the subject of several research reports. UBS Group upgraded shares of AstraZeneca from a “sell” rating to a “neutral” rating in a research note on Wednesday, November 20th. Deutsche Bank Aktiengesellschaft upgraded shares of AstraZeneca from a “sell” rating to a “hold” rating in a report on Wednesday, November 6th. Two investment analysts have rated the stock with a hold rating, six have given a buy rating and two have issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Buy” and a consensus target price of $89.75.
Get Our Latest Analysis on AstraZeneca
Institutional Trading of AstraZeneca
AstraZeneca Stock Down 0.5 %
AstraZeneca stock traded down $0.31 during trading hours on Friday, hitting $66.60. The stock had a trading volume of 5,419,360 shares, compared to its average volume of 4,140,949. The stock’s 50-day moving average price is $66.11 and its 200-day moving average price is $74.49. AstraZeneca has a 12-month low of $60.47 and a 12-month high of $87.68. The company has a quick ratio of 0.71, a current ratio of 0.93 and a debt-to-equity ratio of 0.71. The stock has a market capitalization of $206.50 billion, a P/E ratio of 31.87, a price-to-earnings-growth ratio of 1.05 and a beta of 0.46.
AstraZeneca (NASDAQ:AZN – Get Free Report) last announced its quarterly earnings data on Tuesday, November 12th. The company reported $1.04 earnings per share for the quarter, topping analysts’ consensus estimates of $1.01 by $0.03. The company had revenue of $13.57 billion during the quarter, compared to analyst estimates of $13.08 billion. AstraZeneca had a net margin of 12.68% and a return on equity of 30.01%. The firm’s revenue for the quarter was up 18.0% on a year-over-year basis. During the same period in the previous year, the business earned $0.87 EPS. Equities research analysts anticipate that AstraZeneca will post 4.11 EPS for the current fiscal year.
AstraZeneca Company Profile
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.
Further Reading
- Five stocks we like better than AstraZeneca
- How to Use the MarketBeat Excel Dividend Calculator
- Top ETFs That Beat the Market in 2024 and Could Do It Again
- 3 Warren Buffett Stocks to Buy Now
- J.B. Hunt Leads Truckers Lower: Buy Them While They’re Down?
- What is a buyback in stocks? A comprehensive guide for investors
- MarketBeat Week in Review – 01/13 – 01/17
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.